<DOC>
	<DOCNO>NCT00637052</DOCNO>
	<brief_summary>This 2-phase study patient select myeloid leukemia advance myelodysplastic syndrome ( MDS ) , fail , refuse eligible standard treatment , receive investigational study drug ARRY-520 . The study 3 part . The first phase study , Phase 1 , 2 part . In first part Phase 1 , patient select myeloid leukemia advance MDS receive increase dos study drug different schedule order achieve high dose possible cause unacceptable side effect . Approximately 30 patient ( per schedule ) US enrol Part 1 ( Completed ) . In second part Phase 1 , patient advance MDS receive best dose study drug schedule determine first part study . Approximately 10 patient US enrol Part 2 ( Completed ) . In third part study , Phase 2 , patient acute myeloid leukemia ( AML ) advance MDS receive best dose study drug schedule determine first part study follow see side effect study drug cause see effectiveness , , treat cancer . Approximately 40 patient US enrol Part 3 ( Withdrawn ) .</brief_summary>
	<brief_title>A Study ARRY-520 Patients With Advanced Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Key Inclusion Criteria ( Part 2 ) : Patients either Intermediate2 High risk MDS AML ( &gt; 20 % bone marrow blast ) stable low normal white blood cell count ( WBC ) . Patients fail one prior chemotherapy regimen include hypomethylating agent . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 . Discontinuation prior treatment least 2 week prior start study . Adequate hepatic renal function . Additional criterion exist . Key Exclusion Criteria ( Part 2 ) : Concurrent cytotoxic therapy , biological , endocrine immunological response modifier . Previous radiation &gt; 25 % bone marrow . Other active malignancy . Known positive serology human immunodeficiency virus ( HIV ) . Central nervous system involvement document spinal fluid cytology . Active , uncontrolled infection . Additional criterion exist</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>preleukemia</keyword>
	<keyword>dysplasia myeloid blood cell</keyword>
</DOC>